scholarly journals Auditing Protein Therapeutics Management by Professional APCs: Toward Prevention of Immune Responses against Therapeutic Proteins

2008 ◽  
Vol 181 (3) ◽  
pp. 1609-1615 ◽  
Author(s):  
Suryasarathi Dasgupta ◽  
Jagadeesh Bayry ◽  
Sebastien André ◽  
Jordan D. Dimitrov ◽  
Srinivas V. Kaveri ◽  
...  
Keyword(s):  
Immune Responses ◽  
Therapeutic Proteins ◽  
Protein Therapeutics

Protein Therapeutics: An Updated Review

2021 ◽  
Vol 11 (3) ◽  
pp. 253-257
Author(s):  
Arindam Chakraborty ◽  
Dipak Kumar Singha ◽  
Manas Chakraborty ◽  
Payel Mukherjee
Keyword(s):  
Stability Problem ◽  
Clinical Success ◽  
Treatment Options ◽  
Therapeutic Proteins ◽  
Protein Therapeutics ◽  
Therapeutic Protein ◽  
Recent Advancement ◽  
Pharmaceutical Industries ◽  
Day By Day ◽  
Pharmaceutical Biotechnology

Therapeutic protein are one of the prime option of biologicals as per their clinical uses. In recent times, uses of therapeutic protein increases day by day. Protein therapeutics are used extensively to treat various diseases like cancer, AIDS etc. Due to recent advancement in pharmaceutical biotechnology the interest towards therapeutic proteins are augmenting nowadays. Various clinical research are going on in this field to treat different diseases and pharmaceutical industries are also make interest on therapeutic proteins. Among the various treatment options therapeutic protein will provide highest chance of clinical success. Some recent clinical trials demonstrate that therapeutic protein may provide the safe and potential option to treat various diseases, but there are some drawbacks also like some immunogenic issues, safety, stability problem of protein, degradation of protein in various conditions.

scholarly journals The NMR Spectral Measurement Database: A System for Organizing and Accessing NMR Spectra of Therapeutic Proteins

2021 ◽  
Vol 126 ◽  
Author(s):  
Niksa Blonder ◽  
Frank Delaglio
Keyword(s):  
Nuclear Magnetic Resonance ◽  
Magnetic Resonance ◽  
Spectral Data ◽  
Data Storage ◽  
Nmr Spectra ◽  
Therapeutic Proteins ◽  
Data Access ◽  
Protein Therapeutics ◽  
Spectral Measurement ◽  
Storage And Retrieval

The Nuclear Magnetic Resonance Spectral Measurement Database (NMR-SMDB) was developed for the purpose of organizing and searching NMR spectral data of protein therapeutics, linking spectra to corresponding sample information and enabling quick access to full datasets and entire studies. In addition to supporting internal research at the National Institute of Standards and Technology (NIST), the system could facilitate data access to stakeholders outside of NIST, and future versions of the database software itself could be installed by others for their own data storage and retrieval.

Regulation of immune responses to protein therapeutics by transplacental induction of T cell tolerance

2015 ◽  
Vol 7 (275) ◽  
pp. 275ra21-275ra21 ◽  
Author(s):  
Nimesh Gupta ◽  
Slobodan Culina ◽  
Yann Meslier ◽  
Jordan Dimitrov ◽  
Christophe Arnoult ◽  
...  
Keyword(s):  
T Cell ◽  
Immune Responses ◽  
Protein Therapeutics ◽  
T Cell Tolerance ◽  
Cell Tolerance ◽  
Transplacental Induction

scholarly journals Distribution and elimination of protein therapeutics: A review

2012 ◽  
Vol 4 (2) ◽  
pp. 1-12 ◽  
Author(s):  
Kumar Bishwajit Sutradhar ◽  
Sabera Khatun ◽  
Abdullah Al Mamun ◽  
Mamotaz Begum
Keyword(s):  
Review Paper ◽  
Therapeutic Proteins ◽  
Coagulation Factors ◽  
Protein Therapeutics ◽  
Small Molecule Drugs ◽  
Conventional Drug ◽  
General Aspects ◽  
Near Future ◽  
Stimulating Factor

It was 1980s when the first therapeutic protein was launched in the market. It was recombinant DNAderived insulin. Since its inception, within the worldwide pharmaceutical sector, protein therapeutics has been enjoying the fastest growth, notably for the last few years. As a result it is assumed that the treatment methodology with the conventional drug therapy will be shifted towards therapeutic proteins in near future. It made revolution in the treatment of chronic diseases like cancer, diabetes, cardiovascular diseases. The major segments in protein therapeutics are monoclonal antibody, insulin, granulocyte-colony stimulating factor (G-CSF), coagulation factors etc. In this review paper we will discuss the general aspects of protein therapeutics with their advantages over small-molecule drugs, functional classification of therapeutic proteins and their uses. The pharmacokinetics of protein therapeutics, especially from the distribution and elimination characteristics of therapeutic proteins will be discussed in brief with relevant examples. The major challenges and future perspectives will also be presented in short. DOI: http://dx.doi.org/10.3329/sjps.v4i2.10433 S. J. Pharm. Sci. 4(2) 2011: 01-12

scholarly journals Size-based Degradation of Therapeutic Proteins - Mechanisms, Modelling and Control

2021 ◽  
Vol 12 (1) ◽  
pp. 68-84
Author(s):  
Rohit Bansal ◽  
Saurabh Kumar Jha ◽  
Niraj Kumar Jha
Keyword(s):  
Protein Degradation ◽  
Therapeutic Proteins ◽  
Protein Therapeutics ◽  
Degradation Pathways ◽  
High Demand ◽  
Fragmentation Pathways ◽  
Great Demand ◽  
And Control

Abstract Protein therapeutics are in great demand due to their effectiveness towards hard-to-treat diseases. Despite their high demand, these bio-therapeutics are very susceptible to degradation via aggregation, fragmentation, oxidation, and reduction, all of which are very likely to affect the quality and efficacy of the product. Mechanisms and modelling of these degradation (aggregation and fragmentation) pathways is critical for gaining a deeper understanding of stability of these products. This review aims to provide a summary of major developments that have occurred towards unravelling the mechanisms of size-based protein degradation (particularly aggregation and fragmentation), modelling of these size-based degradation pathways, and their control. Major caveats that remain in our understanding and control of size-based protein degradation have also been presented and discussed.

Correlation of in silico prediction of immunogenicity of therapeutic proteins with immune responses in clinical studies.

2008 ◽  
Vol 22 (S2) ◽  
pp. 563-563
Author(s):  
Vibha Jawa ◽  
Daniel Mytych ◽  
Michael Moxness ◽  
Don Zhong ◽  
Steven Swanson ◽  
...  
Keyword(s):  
Immune Responses ◽  
Clinical Studies ◽  
In Silico ◽  
Therapeutic Proteins ◽  
In Silico Prediction

scholarly journals Engineered binding to erythrocytes induces immunological tolerance to E. coli asparaginase

2015 ◽  
Vol 1 (6) ◽  
pp. e1500112 ◽  
Author(s):  
Kristen M. Lorentz ◽  
Stephan Kontos ◽  
Giacomo Diaceri ◽  
Hugues Henry ◽  
Jeffrey A. Hubbell
Keyword(s):  
Immune Responses ◽  
Therapeutic Proteins ◽  
Tolerance Induction ◽  
Immunological Tolerance ◽  
Drug Candidates ◽  
Humoral Immune ◽  
Humoral Immune Responses ◽  
Clinical Complications ◽  
Erythrocyte Binding

Antigen-specific immune responses to protein drugs can hinder efficacy and compromise safety because of drug neutralization and secondary clinical complications. We report a tolerance induction strategy to prevent antigen-specific humoral immune responses to therapeutic proteins. Our modular, biomolecular approach involves engineering tolerizing variants of proteins such that they bind erythrocytes in vivo upon injection, on the basis of the premise that aged erythrocytes and the payloads they carry are cleared tolerogenically, driving the deletion of antigen-specific T cells. We demonstrate that binding the clinical therapeutic enzyme Escherichia colil-asparaginase to erythrocytes in situ antigen-specifically abrogates development of antibody titers by >1000-fold and extends the pharmacodynamic effect of the drug 10-fold in mice. Additionally, a single pretreatment dose of erythrocyte-binding asparaginase tolerized mice to multiple subsequent doses of the wild-type enzyme. This strategy for reducing antigen-specific humoral responses may enable more effective and safer treatment with therapeutic proteins and drug candidates that are hampered by immunogenicity.

Sign in / Sign up

Export Citation Format

Share Document